CTTI analysis finds too many clinical trials too small to be useful
Small, single-centre trials dominate the clinical studies logged on US-based registry ClinicalTrials.gov between 2007 and 2010, a new analysis has found.
Read MoreAuthor: Peter Mansell
US government leads global health R&D funding, report finds
The US government is the world’s leading funder of global health research and development, investing more than US$12.7 billion over the past 10 years in new vaccines, drugs, diagnostics and other products for neglected diseases of the developing world, a new report has found.
Read MoreLilly opens £5.4 million research building on Erl Wood campus
Eli Lilly has underlined its commitment to the UK as a research base, and to neuroscience research in particular, by opening new early-stage facilities at its Erl Wood R&D centre in Surrey.
Read MorePRA to be sole CRO provider for Amgen’s Phase III biosimilar trials
After taking a stake in the emerging biosimilars market last December through a partnership with Watson Pharmaceuticals, Amgen has announced an exclusive agreement with clinical research organisation (CRO) PRA to conduct Phase III biosimilar trials.
Read MoreParexel raises revenue guidance as Q3 operating income jumps 29%
After tightening up its financial guidance for fiscal year 2012 at the second-quarter stage, Parexel was on a more bullish track in the three months ended 31 March, raising its revenue forecast for the year and outpacing analysts’ expectations as operating income jumped 29% despite continuing restructuring charges.
Read More- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
